Kenvue Inc. (NYSE:KVUE) Announces Quarterly Dividend of $0.21

Kenvue Inc. (NYSE:KVUE) declared a quarterly dividend on Friday, January 17th,Wall Street Journal reports. Stockholders of record on Wednesday, February 12th will be paid a dividend of 0.205 per share on Wednesday, February 26th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th.

Kenvue has a dividend payout ratio of 63.1% indicating that its dividend is sufficiently covered by earnings. Research analysts expect Kenvue to earn $1.20 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Stock Performance

KVUE traded down $0.09 on Friday, hitting $21.11. 11,266,934 shares of the stock traded hands, compared to its average volume of 9,329,272. The business has a fifty day moving average price of $22.47 and a two-hundred day moving average price of $21.64. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue has a 52 week low of $17.67 and a 52 week high of $24.46. The firm has a market capitalization of $40.46 billion, a PE ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 earnings per share. The business’s revenue was down .4% compared to the same quarter last year. On average, research analysts predict that Kenvue will post 1.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on KVUE. Bank of America boosted their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. UBS Group reduced their target price on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating on the stock in a research note on Thursday. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a report on Friday. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.